Global Clinical Diagnostics Outlook, 2024
Driven by Digital Services and Automation, the Molecular Diagnostics and POCT Sectors Rebound after the COVID-19 Pandemic
18-Apr-2024
Global
Market Outlook
With the end of the COVID-19 pandemic, healthcare providers have been directing most of their capabilities toward preventive healthcare and precision medicine, as the clinical diagnostics industry continues its transition from a centralized to a decentralized testing model. Globally, 2024 is set to be a profitable year for the industry, which will likely witness sustained growth through to 2029. The main growth drivers will be the point-of-care testing (POCT) and molecular diagnostics sectors, which Frost & Sullivan expects to rebound even more strongly in 2024.
This study examines clinical diagnostics industry trends and growth projections from 2024 to 2029 across five global regions. It analyzes innovative in vitro diagnostics technologies and applications, major vendors to watch, and growth opportunities in the post-pandemic reality. The research also provides the top 5 predictions for 2024 related to the industry’s decentralization trend, the recovery of molecular diagnostics, and the higher investments in automated solutions and novel digital models.
Analysis Highlights
The 2023 Clinical Diagnostics Industry: Forecast vs. Actual
Top Clinical Diagnostics Predictions for 2024
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on the Clinical Diagnostics Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Segmentation
Growth Environment
Growth Environment (continued)
Top 10 Trends for 2024
Top 10 Growth Opportunities
1. Global GDP Growth—Mild Global Growth Slowdown from 3.0% in 2023 to 2.6% in 2024 as Key Economies Lose Growth Momentum
2. Inflation and Interest Rates—Headline Inflation to Continue to Decline; H2 2024 Shift Toward Rate Cuts for Advanced Economies
3. Currency Trajectory—Dollar to Remain Strong in H1 2024; Emerging Market Currencies to Get Boost from Q3 2024 Onwards
4. Labor Market—Moderate Unemployment Uptick; Positive Expectations Over Market Sentiment to Support Labor Hoarding
5. Oil Markets—Q1 OPEC+ Oil Production Cuts; Non-OPEC Production to Rise
6. Critical Minerals Supplies—Need for Economic Resiliency to Bolster Cross-border and Cross-industry Partnerships
7. North America—Economic Slowdown Amidst Discretionary Spending Pullback and Elevated Interest Rates
8. Western Europe—Moderate Growth Pick-up as Inflation Headwinds Ease Gradually; Rebuilding Fiscal Buffers to Take Precedence
9. Middle East—Non-oil Growth Driven by Economic Diversification to Limit Pullback Caused by a Slowdown in Global Oil Markets
10. Asia—Emerging Economies to Drive Growth Momentum; Fiscal Measures to Support Chinese Economic Recovery
Forecast Assumptions: Clinical Diagnostics Industry
Clinical Diagnostics Industry by Segment
Revenue Forecast by Subsegment
Revenue Forecast by Subsegment (continued)
Revenue Forecast by Segment: Centralized Testing
Revenue Forecast by Segment: Referral & Peripheral and Decentralized Testing
Revenue Forecast by Region
Revenue Forecast by Region (continued)
Percent Revenue Forecast by Region
Revenue Forecast Analysis by Region
Revenue Forecast Analysis by Region (continued)
Competitive Environment
Revenue Share
Revenue Share Analysis
Competitor Matrix
Competitor Matrix (continued)
Notable M&As in 2023
M&As: Historical Analytics
Prediction 1: Long-term Change in Consumer Behavior Supports Expansion into Self-collection Testing
Prediction 2: Staff Shortages Continue to Drive Double-digit Lab Automation Growth Rate
Prediction 3: Adoption of NGS and Specialized Bioinformatics Tools Will Support Pharma Innovation
Prediction 4: ctDNA Analysis Will Expand the Application of MRD Testing for Precision Oncology
Prediction 5: Partnerships with AI-focused Start-ups to Promote Adoption of AI-based Digital Pathology in Clinical Segments
2024 Industry Snapshot
Clinical Chemistry and Immunoassays Industry Snapshot
Clinical Chemistry and Immunoassays Industry: Companies to Watch
Molecular Diagnostics Industry Snapshot
Molecular Diagnostics Industry: Companies to Watch
POCT Industry Snapshot
POCT Industry: Companies to Watch
Tissue Diagnostics Industry Snapshot
Tissue Diagnostics Industry: Companies to Watch
Growth Opportunity 1: Shift toward Digital Diagnostics Services
Growth Opportunity 1: Shift toward Digital Diagnostics Services (continued)
Growth Opportunity 2: Expansion of Clinical Chemistry and Immunoassays to Emerging Markets
Growth Opportunity 2: Expansion of Clinical Chemistry and Immunoassays to Emerging Markets (continued)
Growth Opportunity 3: Predictive Testing in Molecular Diagnostics for Genetics and Cardiovascular Diseases
Growth Opportunity 3: Predictive Testing in Molecular Diagnostics for Genetics and Cardiovascular Diseases (continued)
Growth Opportunity 4: Molecular POCT in Clinical Settings
Growth Opportunity 4: Molecular POCT in Clinical Settings (continued)
Growth Opportunity 5: Multiplex POCT for Immunoassay, STI, and AMR Applications
Growth Opportunity 5: Multiplex POCT for Immunoassay, STI, and AMR Applications (continued)
Conclusions and Future Outlook
Your Next Steps
Why Frost, Why Now?
List of Exhibits
Legal Disclaimer
Purchase includes:
- Report download
- Growth Dialog™ with our experts
Growth Dialog™
A tailored session with you where we identify the:- Strategic Imperatives
- Growth Opportunities
- Best Practices
- Companies to Action
Impacting your company's future growth potential.
Deliverable Type | Market Outlook |
---|---|
Author | Lucila Martin |
Industries | Chemicals and Materials |
No Index | No |
Is Prebook | No |
Podcast | No |
WIP Number | KA03-01-00-00-00 |